

# The Age-Related Metabolic Program


October 16, 2019

# Forward Looking Statements

The matters discussed in this presentation include forward looking statements which are subject to various risks, uncertainties, and other factors that could cause actual results to differ materially from the results anticipated. Such risks and uncertainties include but are not limited to the success of AgeX Therapeutics and its affiliates in developing new stem cell-based products and technologies; results of clinical trials of such products; the ability of AgeX and its licensees to obtain additional FDA and foreign regulatory approval to market products; competition from products manufactured and sold or being developed by other companies; the price of and demand for such products; the ability of AgeX and its subsidiaries to maintain patent and other intellectual property rights; and the ability of AgeX to raise the capital needed to finance its current and planned operations. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. As actual results may differ materially from the results anticipated in these forward-looking statements they should be evaluated together with the many uncertainties that affect the business of AgeX and its other subsidiaries, particularly those mentioned in the cautionary statements found in AgeX's Securities and Exchange Commission filings. AgeX disclaims any intent or obligation to update these forward-looking statements.





#### Developmental Somatic Restriction






### Examples of SR Metabolic Markers









Fetal Brown Adipocytes


PureStem Brown Adipocytes









# Reciprocal Expression of CPT1B and COX7A1








#### In Vivo Association with Frailty



#### J Cachexia Sarcopenia Muscle. 2016 Dec;7(5):604-614

Expression of protocadherin gamma in skeletal muscle tissue is associated with age and muscle weakness

Figure 5 Scheme summarizing the major findings of this study.





# Reprogramming Age-Related Metabolism

